The shortage of available donor allografts continues to provoke a health care crisis and provides the rationale for continued xenotransplantation research. We are attempting to address these issues by inducing transplantation tolerance across discordant xenogeneic barriers in non-human primates. Our strategy utilizes composite vascularized thymic-renal grafts from GalT-KO swine. During the most recent project period (late 2004-2008), we markedly decreased the complication rate in the induction period with a "modified regimen," which eliminated steroids and whole body irradiation. Our most significant findings are (1) Extended average survival of life-supporting kidney xenograft recipients to greater than 50 days under the modified immunosuppression regimen as compared to 33 days under the original protocol;(2) Reproducible in vitro evidence for donor-specific tolerance;and (3) Demonstration of CD4/CD8 double positive baboon xenothymocytes in transplanted pig thymic grafts, indicating baboon thymopoiesis, which had otherwise not been achieved in a large animal xenotransplant model. To our knowledge, these results represent the longest average survival of life-supporting xenografts and also provide novel in vitro evidence for tolerance in large animals. In order to make this approach more clinically applicable, this proposal will address remaining crucial concerns of tolerance induction, immune suppression, and issues with renal xenograft function in baboons that may be caused by molecular incompatibilities across species.
In Aim 1, we will first confirm immunologic tolerance induced by xenogeneic porcine vascularized thymic grafts and eliminate maintenance immunosuppression using our most successful regimen. We will also attempt to achieve tolerance with a T-cell depletion based regimen in order to remove anfi-CD154 mAb and myelosuppressive drugs.
In Aim 2, we will assess in-vitro parameters of xenogeneic immunity before and after transplantation of vascularized thymic tissue. We will examine the fundamental cellular processes involved in the development and maintenance of tolerance.
In Aim 3, we will evaluate the cause of xenograft kidney proteinuria and develop preventive strategies. We will explore: 1) the utility of anti-non-Gal antibody removal prior to graft implantation;2) pharmacologic adjuvant vascular protective therapies shown to be clinically effective for treatment of vascular injury/proteinuria;and 3) the use of kidneys from GalT-KO pigs with additional transgenes, including hDAF, hCD39 and thrombomodulin. The success of a clinically applicable strategy would provide not only a limitiess supply of donor organs but also opportunities for transplantation in patients unable to receive a transplant because of presensitization to allogeneic human donors.

Public Health Relevance

The cure for end stage organ disease is allo-transplantation;however, there is a critical organ donor shortage. We have previously demonstrated life supporting porcine renal xenograft survival up to 3 months in nonhuman primates by using innovative strategies of T-cell re-education through co-transplantation of a vascularized thymus with kidneys from genetically modified miniature swine. The clinical applicability unique to this proposal will allow us to address the remaining issues of tolerance induction, immunity and molecular incompatibilities across a xenogeniec barrier. The benefits of clinically applicable xenotransplantation include decreases in medical costs and limitless organ supply, as well as the ability to provide recipients previously unable to receive a transplant because of presensitization to human donors or recurrent disease (e.g Hepatitis C), with a life-saving organ.

Agency
National Institute of Health (NIH)
Type
Research Program Projects (P01)
Project #
5P01AI045897-14
Application #
8688873
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Peraino, Jaclyn Stromp; Zhang, Huiping; Rajasekera, Priyani V et al. (2014) Diphtheria toxin-based bivalent human IL-2 fusion toxin with improved efficacy for targeting human CD25(+) cells. J Immunol Methods 405:57-66
Yamada, Kazuhiko; Tasaki, Masayuki; Sekijima, Mitsuhiro et al. (2014) Porcine cytomegalovirus infection is associated with early rejection of kidney grafts in a pig to baboon xenotransplantation model. Transplantation 98:411-8
Wang, Yuantao; Wang, Hui; Bronson, Roderick et al. (2014) Rapid dendritic cell activation and resistance to allotolerance induction in anti-CD154-treated mice receiving CD47-deficient donor-specific transfusion. Cell Transplant 23:355-63
Navarro-Alvarez, Nalu; Yang, Yong-Guang (2014) Lack of CD47 on donor hepatocytes promotes innate immune cell activation and graft loss: a potential barrier to hepatocyte xenotransplantation. Cell Transplant 23:345-54
Kalscheuer, Hannes; Onoe, Takashi; Dahmani, Alexander et al. (2014) Xenograft tolerance and immune function of human T cells developing in pig thymus xenografts. J Immunol 192:3442-50
Tasaki, Masayuki; Shimizu, Akira; Hanekamp, Isabel et al. (2014) Rituximab treatment prevents the early development of proteinuria following pig-to-baboon xeno-kidney transplantation. J Am Soc Nephrol 25:737-44
Tena, A; Kurtz, J; Leonard, D A et al. (2014) Transgenic expression of human CD47 markedly increases engraftment in a murine model of pig-to-human hematopoietic cell transplantation. Am J Transplant 14:2713-22
Scalea, Joseph R; Villani, Vincenzo; Gillon, Bradford C et al. (2014) Development of antidonor antibody directed toward non-major histocompatibility complex antigens in tolerant animals. Transplantation 98:514-9
Sekijima, Mitsuhiro; Waki, Shiori; Sahara, Hisashi et al. (2014) Results of life-supporting galactosyltransferase knockout kidneys in cynomolgus monkeys using two different sources of galactosyltransferase knockout Swine. Transplantation 98:419-26
Haspot, F; Li, H W; Lucas, C L et al. (2014) Allospecific rejection of MHC class I-deficient bone marrow by CD8 T cells. Am J Transplant 14:49-58

Showing the most recent 10 out of 116 publications